Lrig1 is a positive prognostic marker in hepatocellular carcinoma
Authors Yang B, Dai C, Tan RM, Zhang B, Meng X, Ye J, Wang XQ, Wei L, He F, Chen ZS
Received 11 May 2016
Accepted for publication 17 September 2016
Published 15 November 2016 Volume 2016:9 Pages 7071—7079
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Ram Prasad
Peer reviewer comments 3
Editor who approved publication: Dr Jianmin Xu
Bo Yang,1,2 Chen Dai,1,2 Rumeng Tan,1,2 Bo Zhang,1,2 Xiao Meng,3 Jing Ye,3 Xinqiang Wang,1,2 Lai Wei,1,2 Fan He,4 Zhishui Chen1,2
1Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China; 2Key Laboratory of Ministry of Health and Key Laboratory of Ministry of Education, Wuhan, Hubei, People’s Republic of China; 3Department of Pathology, Liaocheng People’s Hospital, Liaocheng, Shandong, People’s Republic of China; 4Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China
Background: The prevalence of hepatocellular carcinoma (HCC) is increasing worldwide. As a consequence, there is an urgent need for identifying molecular markers of HCC development and progression. Recently, several studies have suggested that the Lrig1 may have prognostic implications in various cancer types, but its clinical value in HCC is not well evaluated.
Materials and methods: In this study, the expression level of Lrig1 was examined in 133 HCC tissues and adjacent normal tissues by immunohistochemistry. Furthermore, potential associations between Lrig1 expression and the carcinoma clinical parameters were investigated, including recurrence and survival rate. We silenced the Lrig1 in the normal liver cell line (LO2) and liver cancer cell line (Hep-G2) in vitro by the small interference RNA and detected its influence on proliferation, migration, and invasion.
Results: The expression of Lrig1 was significantly downregulated in liver cancer tissues and cell lines, and its expression levels were related to tumor size, tumor–node–metastasis staging and tumor recurrence. Furthermore, analysis of 6-year survival of 133 HCC patients showed that those with stronger Lrig1 expression had significantly longer overall survival time than those with weaker Lrig1 expression. In addition, decreased expression of Lrig1 in vitro promoted the growth, migration, or invasion of normal liver cells and cancer cells.
Conclusion: Our findings demonstrate that Lrig1 could serve as a potential marker in the prognosis of patients with HCC. We also revealed that Lrig1 might be involved in the metastatic progression of liver cancer. However, its clinical value should be further investigated in the future.
Keywords: Lrig1, hepatocellular carcinoma, prognosis, immunohistochemistry, siRNA, invasion, migration
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]